Comments on the paper "The effectiveness of serogroup C meningococcal vaccine estimated from routine surveillance data" [P. Rivest, R. Allard, Vaccine 20 (2002) 2533-2536] [2] (multiple letters)

Vaccine

Volumn 21, Issue 19-20, 2003, Pages 2260-2261

  De Wals, Philippe ^a   De Serres, Gaston ^a   Allard, Robert ^b,c,d   Rivest, Paul ^b,c  

^a UNIVERSITÉ LAVAL   (Canada)

^b Gouvernement du Quebec   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

AGE DETERMINATION; CALCULATION; CANADA; COHORT ANALYSIS; DISEASE CLASSIFICATION; DRUG EFFICACY; HEALTH STATUS; HEALTH SURVEY; HUMAN; IMMUNIZATION; INCIDENCE; INFECTION RISK; LETTER; MEDICAL ASSESSMENT; MENINGITIS; NORTH AMERICA; PRIMARY SCHOOL; PRIORITY JOURNAL; SEROTYPE; STATISTICAL ANALYSIS;

EID: 0038065327     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00091-4     Document Type: Letter

References (6)

1. W.A. Orenstein R.H. Bernier A.R. Hinman Assessing vaccine efficacy in the field Epidemiol. Rev. 10 1988 212 241
2. C.V. Broome R.R. Facklam D.W. Fraser Pneumococcal disease after pneumococcal vaccination. An alternative method to estimate the efficacy of pneumococcal vaccine N. Engl. J. Med. 303 1980 549 552
3. P. Rivest R. Allard The effectiveness of serogroup C meningococcal vaccine estimated from routine surveillance data Vaccine 20 2002 2533 2536
4. P. De Wals G. De Serres T. Niyonsenga Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec JAMA 285 2001 177 181
5. Pollard AJ, Scheifele D, Rosenstein N. Epidemiology of meningococcal disease in North America. In: Meningococcal Disease. Methods and Protocols. Totowa (NJ): Humana Press; 2001. p. 341–56.
6. L. Erickson P. De Wals Complications and sequelae of meningococcal disease in Quebec, Canada, 1990–1994 Clin. Infect. Dis. 26 1998 1159 1164